US 11,787,810 B2
Diacylglyceride O-acyltransferase 2 inhibitors
Yeon-Hee Lim, South San Francisco, CA (US); Cedric Lorenz Hugelshofer, Oakland, CA (US); Victor W. Mak, South San Francisco, CA (US); James Patrick Roane, Brisbane, CA (US); Jillian R. Sanzone, San Francisco, CA (US); Samantha E. Shockley, San Francisco, CA (US); and Rose Yen, San Francisco, CA (US)
Assigned to Merck Sharp & Dohme LLC, Rahway, NJ (US)
Filed by Merck Sharp & Dohme Corp., Rahway, NJ (US)
Filed on May 13, 2021, as Appl. No. 17/319,121.
Claims priority of provisional application 63/026,263, filed on May 18, 2020.
Prior Publication US 2021/0363147 A1, Nov. 25, 2021
Int. Cl. C07D 231/56 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 409/14 (2006.01)
CPC C07D 487/04 (2013.01) [C07D 231/56 (2013.01); C07D 409/14 (2013.01); C07D 471/04 (2013.01)] 13 Claims
 
1. A compound of Formula I,

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein
R1 is

OG Complex Work Unit Chemistry
R2 is

OG Complex Work Unit Chemistry
and
R3 is

OG Complex Work Unit Chemistry